Veradermics director John W. Childs disposes of USD 10.18 million in common sharesPUBT·Aug 14 at 05:04 PMMANE-3.98%
We Think Veradermics (NYSE:MANE) Can Afford To Drive Business GrowthSimplywall·Aug 14 at 06:47 AMMANE-3.98%
Buy Rating Reaffirmed on Strong VDPHL01 Data and Catalyst-Rich Roadmap; Price Target Maintained at $164Tip Ranks·Aug 12 at 01:15 PMMANE-3.98%
Veradermics, Incorporated's Lock-Up Period Set To End on August 3rd (NYSE:MANE)Market Beat·Jul 27 at 12:20 AMMANE-3.98%
Veradermics, Incorporated (MANE) Receives a Buy from LifeSci CapitalTip Ranks·Jul 18 at 04:05 PMMANE-3.98%
Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Datarttnews·Jul 18 at 12:22 AMCELC+0.48%MRK+0.10%
U.S. stock market midday update: VeraDermics up 8.39%, oral hair loss medication clinical benefits boost stock pricePrice Alert·Jul 17 at 12:38 PMMANE-3.98%
Veradermics to present age-subgroup data from VDPHL01 male hair loss trial at AAD Innovation AcademyPUBT·Jul 17 at 06:30 AMMANE-3.98%
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy | MANE Stock NewsStockTitan·Jul 16 at 10:30 PMMANE-3.98%
Veradermics, Incorporated (MANE) Gets a Buy from JefferiesTip Ranks·Jul 16 at 09:15 AMMANE-3.98%RANK+1.09%
Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Datarttnews·Jul 15 at 10:42 PMIOVA+1.72%MANE-3.98%
Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164.benzinga_article·Jul 15 at 12:49 PMMANE-3.98%
Needham & Company LLC Issues Positive Forecast for Veradermics (NYSE:MANE) Stock PriceMarket Beat·Jul 15 at 12:18 PMMANE-3.98%
